These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 2611883)
21. Ergotamine abuse: results of ergotamine discontinuation, with special reference to the plasma concentrations. Ala-Hurula V; Myllylä V; Hokkanen E Cephalalgia; 1982 Dec; 2(4):189-95. PubMed ID: 7159921 [TBL] [Abstract][Full Text] [Related]
22. Long-term ergotamine abuse: effect on adrenergically induced mydriasis. Fanciullacci M; Alessandri M; Pietrini U; Briccolani-Bandini E; Beatrice S Clin Pharmacol Ther; 1992 Mar; 51(3):302-7. PubMed ID: 1312004 [TBL] [Abstract][Full Text] [Related]
23. Endothelin-induced venoconstriction is unaffected by type 2-diabetes: in vivo effect of histamine on the endothelin action on veins. Blöchl-Daum B; Vierhapper H; Eichler HG; Waldhäusl W Arch Int Pharmacodyn Ther; 1992; 316():90-6. PubMed ID: 1530376 [TBL] [Abstract][Full Text] [Related]
24. In vivo characterization of serotonin receptors on hand vein. Panconesi A; Andreini R; Del Bianco PL; Franchi G; Sicuteri F Pharmacol Res Commun; 1988 May; 20(5):433-4. PubMed ID: 3420150 [No Abstract] [Full Text] [Related]
28. Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts. Kodama A; Komori K; Kajikuri J; Itoh T J Vasc Surg; 2009 Sep; 50(3):617-25. PubMed ID: 19700096 [TBL] [Abstract][Full Text] [Related]
29. Monoamine sensitivity of smooth muscle in vivo in nociception disorders. Del Bianco PL; Franchi G; Anselmi B; Sicuteri F Adv Neurol; 1982; 33():391-8. PubMed ID: 6275678 [TBL] [Abstract][Full Text] [Related]
30. Interaction of a potential antimigraine drug (Org GC 94) with the vasomotor action of serotonin. Lamar JC; Hardebo JE Eur J Pharmacol; 1979 Dec; 60(4):263-75. PubMed ID: 527662 [TBL] [Abstract][Full Text] [Related]
31. Dopamine and 5-HT supersensitivity in nonorganic central pain and in morphine abstinence: fortuitous or renal analogy? Sicuteri F; Anselmi B; Del Bianco PL Adv Biochem Psychopharmacol; 1980; 22():523-33. PubMed ID: 7395606 [TBL] [Abstract][Full Text] [Related]
32. Drug abuse in migraine patients. Langemark M; Olesen J Pain; 1984 May; 19(1):81-86. PubMed ID: 6739116 [TBL] [Abstract][Full Text] [Related]
34. [Risks related to the use of ergotamine in the therapy of hemicrania. Description of a case]. Bocchia M; Baldini GG; Bertola G; Zorzoli C Recenti Prog Med; 1991; 82(7-8):390-3. PubMed ID: 1947404 [TBL] [Abstract][Full Text] [Related]
35. Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Verhoeff NP; Visser WH; Ferrari MD; Saxena PR; van Royen EA Cephalalgia; 1993 Oct; 13(5):325-9. PubMed ID: 8242725 [TBL] [Abstract][Full Text] [Related]
36. Drug abuse in chronic headache: a clinico-epidemiologic study. Granella F; Farina S; Malferrari G; Manzoni GC Cephalalgia; 1987 Mar; 7(1):15-9. PubMed ID: 3581158 [TBL] [Abstract][Full Text] [Related]
37. Transcranial Doppler ultrasonographic features during drug withdrawal from drug-induced headache. A transcranial Doppler follow-up study. Haase CG; Diener HC Headache; 1998 Oct; 38(9):679-83. PubMed ID: 15613180 [TBL] [Abstract][Full Text] [Related]
38. [Ergotamine; from headache to heartache]. Slob J; Burgersdijk C; Ruiter JH Ned Tijdschr Geneeskd; 1988 May; 132(20):927-30. PubMed ID: 3374687 [No Abstract] [Full Text] [Related]
39. Ergotamine toxicity and serum concentrations of ergotamine in migraine patients. Graham AN; Johnson ES; Persaud NP; Turner P; Wilkinson M Hum Toxicol; 1984 Jun; 3(3):193-9. PubMed ID: 6430784 [TBL] [Abstract][Full Text] [Related]